Spring Valley Acquisition Corporation II (SVII) Fundamental Analysis & Valuation

NASDAQ:SVII • KYG837521080

Current stock price

12.7 USD
-1.15 (-8.3%)
At close:
12.7 USD
0 (0%)
After Hours:

This SVII fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SVII Profitability Analysis

1.1 Basic Checks

  • SVII had positive earnings in the past year.
  • In the past year SVII has reported a negative cash flow from operations.
SVII Yearly Net Income VS EBIT VS OCF VS FCFSVII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M 4M 6M 8M 10M

1.2 Ratios

Industry RankSector Rank
ROA 9.12%
ROE 9.99%
ROIC N/A
ROA(3y)10.36%
ROA(5y)N/A
ROE(3y)11.02%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SVII Yearly ROA, ROE, ROICSVII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 10 20

1.3 Margins

  • SVII does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SVII Yearly Profit, Operating, Gross MarginsSVII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SVII Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, SVII has less shares outstanding
  • SVII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SVII Yearly Shares OutstandingSVII Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
SVII Yearly Total Debt VS Total AssetsSVII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • SVII has an Altman-Z score of 32.80. This indicates that SVII is financially healthy and has little risk of bankruptcy at the moment.
  • SVII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 32.8
ROIC/WACCN/A
WACCN/A
SVII Yearly LT Debt VS Equity VS FCFSVII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • SVII has a Current Ratio of 0.13. This is a bad value and indicates that SVII is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SVII has a Quick Ratio of 0.13. This is a bad value and indicates that SVII is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
SVII Yearly Current Assets VS Current LiabilitesSVII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SVII Growth Analysis

3.1 Past

  • SVII shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -86.85%.
EPS 1Y (TTM)-86.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-113.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. SVII Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 181.43, the valuation of SVII can be described as expensive.
  • Compared to an average S&P500 Price/Earnings ratio of 25.70, SVII is valued quite expensively.
Industry RankSector Rank
PE 181.43
Fwd PE N/A
SVII Price Earnings VS Forward Price EarningsSVII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SVII Per share dataSVII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SVII Dividend Analysis

5.1 Amount

  • No dividends for SVII!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SVII Fundamentals: All Metrics, Ratios and Statistics

Spring Valley Acquisition Corporation II

NASDAQ:SVII (10/20/2025, 8:17:46 PM)

After market: 12.7 0 (0%)

12.7

-1.15 (-8.3%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)08-13
Earnings (Next)11-12
Inst Owners34.21%
Inst Owner Change-40.19%
Ins Owners1.21%
Ins Owner Change-1.06%
Market Cap125.48M
Revenue(TTM)N/A
Net Income(TTM)2.40M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 181.43
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.22
P/tB 5.22
EV/EBITDA N/A
EPS(TTM)0.07
EY0.55%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS2.43
TBVpS2.43
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.96
Profitability
Industry RankSector Rank
ROA 9.12%
ROE 9.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)10.36%
ROA(5y)N/A
ROE(3y)11.02%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z 32.8
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-86.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-113.97%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.38%
OCF growth 3YN/A
OCF growth 5YN/A

Spring Valley Acquisition Corporation II / SVII Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for Spring Valley Acquisition Corporation II?

ChartMill assigns a fundamental rating of 1 / 10 to SVII.


Can you provide the valuation status for Spring Valley Acquisition Corporation II?

ChartMill assigns a valuation rating of 0 / 10 to Spring Valley Acquisition Corporation II (SVII). This can be considered as Overvalued.


What is the profitability of SVII stock?

Spring Valley Acquisition Corporation II (SVII) has a profitability rating of 0 / 10.


What is the financial health of Spring Valley Acquisition Corporation II (SVII) stock?

The financial health rating of Spring Valley Acquisition Corporation II (SVII) is 5 / 10.